Welcome to our dedicated page for Sanofi FR news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi FR stock.
Sanofi (SNY), a global leader in pharmaceuticals and vaccines, provides critical health solutions through its innovative drug development and strategic partnerships. This dedicated news hub offers investors and industry professionals centralized access to official updates and analysis.
Track SNY's latest press releases covering clinical trial results, regulatory approvals, and financial earnings. Our curated collection simplifies monitoring of key developments in oncology, immunology treatments, and vaccine innovations that shape global healthcare markets.
Discover timely updates on Sanofi's strategic collaborations, manufacturing expansions, and R&D breakthroughs. The resource serves both casual observers and professional analysts seeking unfiltered information about this Paris-based healthcare giant's market activities.
Bookmark this page for streamlined access to SNY's evolving story in the pharmaceutical sector. Verify facts directly from source materials while staying informed about developments impacting one of Europe's most significant healthcare enterprises.
Sanofi (SNY) has announced that Chrissy Teigen has joined as the new celebrity spokesperson for their Screen For Type 1 movement. The partnership, revealed on T1D Day, aims to promote early type 1 diabetes risk detection through screening.
Teigen's involvement stems from her personal experience with her son Miles, who was diagnosed with type 1 diabetes at age six in 2024 after an unexpected medical emergency. This reflects a common scenario, as approximately 64,000 Americans are diagnosed annually with type 1 diabetes, with up to 40% unaware of their condition until experiencing life-threatening complications.
The Screen For Type 1 initiative emphasizes that the disease can be detected through a single blood test that identifies diabetes-related autoantibodies before symptoms appear. While type 1 diabetes cannot be prevented, early detection can help families better prepare and plan for managing the condition.
Sanofi (SNY) has announced the immediate adoption of FDA-selected influenza strains for manufacturing its vaccine portfolio for the 2025-26 flu season in the US. The selected strains match those already in production by the company. Sanofi plans to begin shipping vaccines this summer to healthcare facilities for early season administration.
The announcement comes amid one of the worst flu seasons in decades, with CDC estimates showing 40 million illnesses, 520,000 hospitalizations, and 22,000 deaths through March 1. The company's 2025-26 US portfolio will include FLUZONE® High-Dose, FLUBLOK®, and FLUZONE® vaccines, covering patients from 6 months through 65+ years of age.
Sanofi and Orano Med have entered into an agreement to develop next-generation radioligand medicines for rare cancers. They will invest in a new entity under the Orano Med brand, focusing on discovery, design, and clinical development of radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes. This follows Sanofi's exclusive licensing agreement with Orano Med and RadioMedix for AlphaMedix™.
The collaboration aims to combine Sanofi's biopharma expertise with Orano's nuclear technology to advance cancer treatments. Sanofi will make an equity investment of €300 million, acquiring approximately 16% stake in the new entity valued at €1.9bn. The partnership is expected to accelerate the development of Orano Med's pipeline and leverage its capabilities in lead-212 based therapies.
Both companies are members of the Paris Saclay Cancer Cluster and aim to contribute to the France 2030 plan for oncology innovation. The agreement is subject to standard regulatory approvals.
Sanofi announced that the FDA has updated the label for FLUBLOK (Influenza Vaccine) to include data from a new safety study involving pregnant individuals 18 years and older. The study, involving over 48,000 pregnant individuals across multiple flu seasons, demonstrated that FLUBLOK safety is consistent with a standard-dose flu vaccine and pregnancy-related outcomes in the general population.
Key findings include:
- No increased risk of pregnancy, birth or neonatal/infant outcomes compared to standard-dose flu vaccine
- Similar rates of pregnancy outcomes between FLUBLOK and standard-dose vaccine groups
- Comparable birth and neonatal/infant outcomes between the two groups
The CDC, ACIP, and ACOG recommend flu vaccination for pregnant individuals due to their higher risk for severe illness and complications from flu.
Sanofi is shipping BEYFORTUS (nirsevimab-alip) in the US to protect babies against RSV disease. The company aims to provide access for every eligible baby, with a new FDA-approved manufacturing line expanding capacity to meet demand. BEYFORTUS is the first long-acting monoclonal antibody approved for RSV prevention in newborns and infants up to 24 months old.
Sanofi has collaborated with the White House, CDC, and FDA to ensure wide availability. The company has launched a Reservation Program for private healthcare providers and is working with AstraZeneca to build inventory for current and future seasons. Another filling line is expected to provide doses for the 2024/2025 season, further increasing production capacity.
Sanofi has entered an exclusive licensing agreement with RadioMedix and Orano Med for AlphaMedixTM, a late-stage targeted alpha therapy (TAT) project for treating neuroendocrine tumors (NETs). AlphaMedixTM has received Breakthrough Therapy Designation from the FDA for gastroenteropancreatic NETs. Phase 1 and 2 clinical studies showed a 62.5% durable response rate. Under the agreement, Sanofi will handle global commercialization, while Orano Med will manage manufacturing. RadioMedix and Orano Med will receive a €100 million upfront payment and up to €220 million in sales milestones, plus tiered royalties. This collaboration aligns with Sanofi's focus on oncology innovation and rare cancers.
Sanofi has begun shipping influenza vaccines across the U.S. for the 2024/25 flu season, starting on July 10, with shipments continuing through October. These vaccines, including Fluzone High-Dose, Flublok, and Fluzone, are designed to protect against three strains of influenza identified as the most likely to cause illness this season. Sanofi emphasizes the importance of flu vaccination to reduce risks such as pneumonia and cardiac events, especially in vulnerable populations. The company, a leader in global vaccine distribution, aims to support fall immunization campaigns by supplying healthcare providers, pharmacies, and other immunizers.
I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.
Novavax reported its financial results and operational highlights for Q1 2024, including a co-exclusive licensing agreement with Sanofi for COVID-19 vaccines, a Phase 3 trial for a combination flu-COVID-19 vaccine, and a standalone influenza vaccine. The agreement holds potential multi-billion dollar revenue opportunities for Novavax, including upfront payments, equity investments, milestones, and royalties. Novavax also reduced liabilities by $831 million and achieved $94 million in revenue for Q1 2024. The company's financial position improved, with reduced losses and cash reserves of $496 million as of March 31, 2023.
Novavax and Sanofi have entered into a co-exclusive licensing agreement to co-commercialize a protein-based COVID-19 vaccine and develop novel COVID-19-Influenza combination vaccines. The agreement provides broader access to the vaccine from 2025 onwards and includes a cash and equity investment of approximately $1.2 billion for Novavax. This collaboration aims to accelerate the development of a combination product based on authorized vaccines for enhanced convenience and protection.
